检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:黄青[1] 朱淑琴[2] 洪婷[1] 左婷婷[3] 杨宜花[1] 彭胜男[1]
机构地区:[1]江西中医药大学科技学院临床医学系,江西南昌330004 [2]中山大学附属第五医院病理科,广东深圳519000 [3]江西中医药大学科技学院护理系,江西南昌330004
出 处:《解剖科学进展》2017年第6期602-604,共3页Progress of Anatomical Sciences
基 金:江西省卫生计生委科技计划项目(20173012);江西省卫生计生委中医药科研计划(2014A050);江西省教育厅科学技术研究项目(GJJ14619)
摘 要:目的探讨黄芪甲苷(AS)对IgA肾病(IgAN)大鼠脾免疫细胞和肾功能的影响。方法 SD大鼠随机分为对照组、IgAN组、AS低剂量组和高剂量组(n=10)。免疫组化和体视学方法测脾CD3^+、CD4^+T细胞和CD20^+B细胞数密度,免疫荧光法测肾IgA沉积,全自动生化分析仪测24h尿蛋白,显微镜下镜检尿红细胞数。结果与对照组比,IgAN组脾淋巴细胞数密度升高,肾IgA沉积明显,出现血尿、蛋白尿。AS两组与IgAN组比,淋巴细胞数密度下降,肾IgA减少,血尿、蛋白尿减轻。结论 AS有效下调IgAN大鼠脾免疫功能亢进,减轻症状。Objective To explore the effect of astragaloside Ⅳ on immune cells of spleen and the function of kidney in IgA nephropathy of SD rats. Methods SD rats were randomly divided into four groups: control group, IgA nephropathy group, astragaloside Ⅳ low dose group and astragaloside Ⅳ high dose group(n=10 in each group). The number density of spleen CD3+T cells, CD4+T cells and CD20+B ceils was measured by immunohistochemistry and stereologieal method. The deposition of IgA in the kidney was detected by immunofluoreseence assay. 24h-proteinuria was measured by automatic biochemical analyzer, and urine red blood cell was counted by microscope. Results Compared with the control group, the number density of CD3+T cells, CD4+T cells and CD20+B cells in IgA nephropathy group was higher, with obvious glomerular IgA deposition, hemaluria and proteinuria. Compared with the IgA nephropathy group, the number density of CD3+T cells, CD4+T cells and CD20+B cells decreased in astragaloside Ⅳ low or high dose group, with decreased glomerular IgA deposition, the amount of urinary red blood cells and 24-hour urinary protein excretion. Conclusion Astragaloside Ⅳ can effectively downregulate higher splenic immune function of IgA nephropathy rats.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.31